Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

Terpenes, derived from the Cannabis sativa plant, may be the basis of a medication for fibromyalgia and post-surgical pain ...

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

With a watery consistency, this formula is tops at providing weightless hydration that won't leave behind an unflattering ...

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune ...

Review highlights how vitamin D, particularly its active form calcitriol, modulates immune responses, inflammation, and tumor ...

Modern medicine is experiencing a period of significant advancements and innovations, and at its core is radiopharmaceuticals ...

In April 2025, Kamau Therapeutics announced a study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel ...

This useful study reports a method to detect and analyze a novel post-translational modification, lysine acetoacetylation (Kacac), finding it regulates protein metabolism pathways. The study unveils ...

Suzuki, R. (2025) Evaluation of the Hair Growth-Promoting Effects of Combined Treatment with Hair Growth Stimulants. Health, ...

Visa, Adobe, FICO, ASML, and Costco are top wide-moat stocks in 2025. Visa dominates with 4.3 billion cards globally and a net income of $19.7 billion in 2024. ASML is the sole producer of EUV ...